These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Diphtheria as a model. Introduction of serums and vaccines for scarlet fever and pneumococcal pneumonia. Dowling HF JAMA; 1973 Oct; 226(5):550-3. PubMed ID: 4147662 [No Abstract] [Full Text] [Related]
25. Determination of anti group A streptococcal polysaccharide antibodies in human sera by an hemagglutination technique. Goldstein I; Caravano R Proc Soc Exp Biol Med; 1967 Apr; 124(4):1209-12. PubMed ID: 6024836 [No Abstract] [Full Text] [Related]
26. [A method for the quantitative estimation of antibodies to extracellular esterases produced by group A and B streptococci, and application to the sera of patients with scarlet fever (author's transl)]. Hayano S; Tanaka A Kansenshogaku Zasshi; 1981 May; 55(5):339-45. PubMed ID: 6798138 [No Abstract] [Full Text] [Related]
27. Study of the MAP antibodies in the human streptococcal infections. Mihalcu F Arch Roum Pathol Exp Microbiol; 1979; 38(1):25-32. PubMed ID: 546370 [No Abstract] [Full Text] [Related]
29. [Changes in antistreptococcal antibodies in scarlet fever]. Hamd SS; Guasco C G Mal Infett Parassit; 1967 Jun; 19(6):382-6. PubMed ID: 6051990 [No Abstract] [Full Text] [Related]
30. [Characteristics of antitoxin immunity in scarlet fever]. Fiks LI; Bliumental' KV; Silich VA; Dodonov VN; Sezonova EP Pediatriia; 1972 Feb; 51(2):44-8. PubMed ID: 5036295 [No Abstract] [Full Text] [Related]
31. [Mitogenic activity of erythrogenic toxins. I. Type-specific inhibition of the mitogenic activity of erythrogenic toxins by antitoxic antisera from the rabbit (author's transl)]. Petermann F; Knöll H; Köhler W Zentralbl Bakteriol Orig A; 1978 Apr; 240(3):366-79. PubMed ID: 352038 [No Abstract] [Full Text] [Related]
32. [Relationship between anti-streptokinase levels and hemolytic streptococcal types in scarlet fever]. Shimizu H; Iimura T; Yagishita N; Nagase K Kansenshogaku Zasshi; 1973 Dec; 47(12):522-3. PubMed ID: 4208601 [No Abstract] [Full Text] [Related]
33. Modern trends in the treatment of scarlet fever. McLACHLAN IM Med Press; 1951 Feb; 225(7):147-50. PubMed ID: 14805669 [No Abstract] [Full Text] [Related]
34. PROPERTIES OF TOXOPLASMA LYSATES TOXIC TO RABBITS ON INTRAVENOUS INJECTION. LUNDE MN; JACOBS L J Parasitol; 1964 Feb; 50():49-51. PubMed ID: 14125168 [No Abstract] [Full Text] [Related]
36. [Serological study on scarlet fever]. Nakamizo Y; Tsuji S; Shimizu H Kansenshogaku Zasshi; 1973 Dec; 47(12):519-21. PubMed ID: 4208600 [No Abstract] [Full Text] [Related]
37. [Detection of scarlet fever antitoxin in the human serum with the aid of precipitation reaction]. BACKHAUSZ R; KAMARAS J; OSZTOVICS M Gyermekgyogyaszat; 1954 Jan; 5(1):21-6. PubMed ID: 13151489 [No Abstract] [Full Text] [Related]
38. [Cellular immune skin response in streptococcal infections]. Mihalcu F; Stefănescu M; Plătică C; Mijá T; Marţian I; Roman E Arch Roum Pathol Exp Microbiol; 1973 Jun; 32(2):227-35. PubMed ID: 4750230 [No Abstract] [Full Text] [Related]
39. [Use of passive hemagglutination reaction for detection of antibodies to the L forms of Streptococcus]. Chumachenko NV; Goncharova SA Lab Delo; 1973; 11():681-3. PubMed ID: 4132575 [No Abstract] [Full Text] [Related]